Investigating the effects of integrase inhibitors during pregnancy on child development
Integrase Inhibitors during pregnancy and Neurodevelopmental Outcomes: Underlying Mechanism and Therapeutic Intervention
This study is looking at how the medication Dolutegravir, which some pregnant women take for HIV, might affect the development of their children, and it aims to find ways to make this medicine safer for both moms and their babies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11089494 on NIH RePORTER |
What this research studies
This research focuses on understanding how the antiretroviral drug Dolutegravir (DTG) affects neurodevelopment in children born to mothers who take this medication during pregnancy. The study aims to uncover the mechanisms behind any potential developmental issues and explore therapeutic interventions to make DTG safer for use in pregnant women. By examining both prenatal and postnatal effects, the research seeks to fill critical knowledge gaps regarding the safety of DTG for mothers and their children. Patients may be involved in assessments that evaluate the impact of DTG on child development.
Who could benefit from this research
Good fit: Ideal candidates for this research include pregnant women who are HIV-positive and are considering or currently using Dolutegravir as part of their treatment regimen.
Not a fit: Patients who are not pregnant or who do not have HIV may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer treatment options for pregnant women with HIV, ultimately improving developmental outcomes for their children.
How similar studies have performed: While there is ongoing research into the effects of antiretroviral drugs during pregnancy, this specific investigation into DTG's neurodevelopmental impact is relatively novel.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Bade, Aditya N — University of Nebraska Medical Center
- Study coordinator: Bade, Aditya N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.